Mimetogen Pharmaceuticals receives series B financing

Guest Contributor
March 2, 2011

Montreal-based Mimetogen Pharmaceuticals has closed a series B financing round to further develop its neurotrophin mimetics to treat dry eye and other degenerative ocular disorders. The financing is provided by Medwell Capital Inc, which is committing up to $2-million in the privately held, clinical-stage spin off from McGill Univ and Lady Davis Institute for Medical Research. Undisclosed amounts are also being provided by follow-on investors iNovia Capital, MSBi Valorisation and VIMAC Milestone Medica. The funding will allow Mimetogen to complete its Phase II clinical study of MIM-D3 for treatment of moderate to severe dry eye diseaseā€¦.


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.